CJC-1295/Ipamorelin vs Tesamorelin: 2026 Comparison

CJC-1295/ipamorelin and tesamorelin both raise growth hormone but work differently: CJC-1295/ipamorelin combines a GHRH analog with a ghrelin-mimetic secretagogue and sits in a murky FDA compounding gray zone, while tesamorelin is an FDA-approved GHRF analog (EGRIFTA WR/SV) specifically indicated for HIV-associated lipodystrophy. This guide compares mechanism, dosing units, safety data, regulatory status, and cost so you can see where each fits — and how to track either protocol accurately.

Table of Contents

• How These Peptides Actually Work
• CJC-1295/Ipamorelin: The Research-Stack Combo
• Tesamorelin: The FDA-Approved Option
• Dosing Units and Practical Differences
• Safety Profiles Side by Side
• Legal and Regulatory Status
• Cost Considerations
• Alternatives for Abdominal Fat in HIV Lipodystrophy

How These Peptides Actually Work

The core difference between these two protocols comes down to mechanism class. Tesamorelin is a growth hormone-releasing factor (GHRF) analog — it mimics the body’s natural GHRH signal, prompting the pituitary to release growth hormone in a pulsatile pattern that resembles normal physiology, as described in FDA labeling for both EGRIFTA WR and EGRIFTA SV. CJC-1295 is also a GHRH analog, but ipamorelin belongs to a different class entirely: it’s a ghrelin-mimetic growth hormone secretagogue that works through the GH secretagogue receptor rather than the GHRH receptor. Stacking a GHRH analog with a ghrelin mimetic is meant to produce a synergistic GH pulse — two separate signaling pathways converging on the same pituitary output. Tesamorelin, by contrast, is used alone as a single-mechanism GHRF analog. Understanding this distinction matters because it shapes expected pulse amplitude, duration, and how each protocol is dosed and timed in practice.

CJC-1295/Ipamorelin: The Research-Stack Combo

CJC-1295/ipamorelin is one of the most widely used combinations in the peptide research and biohacking community, prized for its dual-pathway approach to stimulating GH release. CJC-1295 extends the half-life of the GHRH signal while ipamorelin adds a clean, selective secretagogue pulse without meaningfully raising cortisol or prolactin — a selectivity often cited as an advantage over older secretagogues. Because the combination is not an FDA-approved drug product, there’s no standardized indication, and dosing protocols vary widely across sources rather than following a single package insert. Trackers using this stack often follow a nightly or twice-daily subcutaneous injection schedule tied to sleep and fasting windows to align with the body’s natural GH pulses. If you’re running this stack, a detailed walkthrough of scheduling and titration is available in our step-by-step dosing protocol guide, and a broader look at what the evidence shows is covered in our CJC-1295 & ipamorelin dosing guide.

Tesamorelin: The FDA-Approved Option

Tesamorelin stands apart because it’s an FDA-approved medication, not a research compound. It’s indicated specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, a use confirmed across multiple FDA label revisions for EGRIFTA WR and EGRIFTA SV. This gives tesamorelin something CJC-1295/ipamorelin lacks: a formal regulatory pathway, standardized manufacturing, and label-directed dosing instructions. The tradeoff is a narrower approved use case — tesamorelin’s label doesn’t cover general anti-aging or broad GH-optimization goals, even though some clinicians use it off-label for those purposes. For readers curious about how tesamorelin behaves once injected, including clearance timing, our tesamorelin half-life breakdown covers that in depth, and our piece on tesamorelin/ipamorelin combination results digs into how it’s sometimes paired with a secretagogue for a fuller GH response.

Dosing Units and Practical Differences

One of the most confusing parts of comparing these protocols is that dosing units aren’t consistent between them. CJC-1295 and ipamorelin research protocols are typically dosed in micrograms (mcg) — commonly in the 100–300 mcg range per compound per injection in community protocols — reflecting their potency at very small quantities. Tesamorelin, by contrast, is dosed in milligrams under its FDA label: Mayo Clinic’s drug monograph lists a standard adult dose of 2 mg injected subcutaneously once daily for the 1 mg vial presentation, with adjusted doses of 1.4 mg daily for the 2 mg vial and 1.28 mg daily for the 11.6 mg vial, since concentration varies by product presentation. That mcg-versus-mg distinction is a common source of dosing errors when people switch between protocols or misread a vial label. Anyone reconstituting either compound benefits from a systematic approach — our peptide reconstitution calculator guide and peptide calculator guide both walk through converting vial concentration into an accurate per-dose volume, which matters far more with mismatched units like these.

Safety Profiles Side by Side

Because tesamorelin is FDA-approved, its adverse event profile is documented through formal labeling and trials tied to its HIV-lipodystrophy indication, giving prescribers a clearer safety baseline than most research peptides offer. CJC-1295/ipamorelin, lacking that same regulatory trial infrastructure, relies more heavily on community-reported experience and smaller research datasets, which makes systematic side-effect tracking especially valuable for anyone running the stack. Commonly reported issues across GH-axis compounds include injection site reactions, water retention, joint stiffness, and headache, though severity and frequency differ by individual and by dose. Because ipamorelin’s selectivity is often marketed as reducing cortisol and prolactin spikes compared to older secretagogues, some users report a milder side-effect profile than with non-selective GH releasers — but this isn’t backed by the same regulatory-grade evidence tesamorelin has. Logging symptoms consistently, with severity scores and timing relative to each dose, is the most reliable way to spot patterns early and adjust before a minor issue becomes a reason to stop a protocol altogether.

Legal and Regulatory Status

The regulatory landscape here is genuinely unsettled, and it’s worth being precise about what’s known versus disputed. Tesamorelin’s status is clear: it’s FDA-approved as EGRIFTA WR and EGRIFTA SV for HIV-associated lipodystrophy, per current FDA labeling. CJC-1295/ipamorelin’s status is murkier and contested across sources. Ipamorelin acetate was reportedly placed in FDA Category 2 under an interim compounding policy, though other reporting suggests that nomination was later withdrawn and it was removed from that category. CJC-1295 was reportedly reviewed by FDA’s Pharmacy Compounding Advisory Committee in December 2024 and was not recommended for inclusion on the 503A bulk drug substances list, a decision with real implications for compounding pharmacies. Because sources disagree on the current, up-to-date status of both compounds, and rules can shift between committee reviews, anyone sourcing either peptide should verify current compounding legality directly with a qualified pharmacy or regulatory reference before starting a protocol, rather than relying on secondhand summaries.

Cost Considerations

Pricing for these two options differs structurally as much as it does in dollar terms. Tesamorelin, as a brand-name FDA-approved therapy, is typically dispensed through a pharmacy with insurance billing codes, copay assistance programs, and manufacturer support tied to its EGRIFTA branding — costs vary widely by insurance coverage and pharmacy benefit design. CJC-1295/ipamorelin, sourced through research or compounding channels outside a standard insurance pathway, is generally priced per vial or per milligram with cash payment, and pricing varies significantly by supplier, purity testing, and region. Neither compound has a single, universal price point, and no neutral, authoritative pricing dataset directly compares the two head-to-head. What’s consistent across both is that inventory management — knowing vial concentration, expiry date, and remaining doses — directly affects real cost per dose, since wasted reconstituted peptide from improper storage or miscalculated draws is one of the most avoidable expenses in any protocol.

Alternatives for Abdominal Fat in HIV Lipodystrophy

Tesamorelin remains the only peptide with a specific FDA-approved indication for excess abdominal fat in HIV-associated lipodystrophy, a use first established in the original EGRIFTA approval and carried through subsequent EGRIFTA WR and EGRIFTA SV label updates. For patients who don’t tolerate tesamorelin or want to explore other GH-axis approaches, some clinicians consider combining it with a secretagogue like ipamorelin to broaden the GH pulse profile, which our tesamorelin/ipamorelin results piece and tesamorelin ipamorelin dosage guide both address in detail. Outside the peptide space, standard approaches to HIV-lipodystrophy fat redistribution include broader metabolic and lifestyle management, though these fall outside tesamorelin’s specific mechanism. Because this is a narrow, medically supervised indication, anyone exploring alternatives should do so with a physician familiar with HIV-related metabolic complications rather than substituting research peptides for an FDA-approved therapy without guidance.

Tracking Either Protocol With Confidence

Whichever path you’re comparing — a GHRH/secretagogue stack or an FDA-approved GHRF analog — the operational challenges look similar: staying consistent with timing, rotating injection sites, watching for early side effects, and not running out of vials mid-cycle. Pep was built for exactly this kind of tracking, letting you log CJC-1295, ipamorelin, or tesamorelin doses alongside symptom severity, site rotation, and inventory status in one place. Rather than juggling a spreadsheet with mismatched mcg and mg units across compounds, Pep’s reconstitution and scheduling tools help keep dosing accurate as you titrate. With 145 compounds supported and adherence tracking built in, it’s designed for anyone treating their protocol like a real, data-driven practice rather than a guess. You can explore how it works at hellopep.io.

Frequently Asked Questions

Can CJC-1295/ipamorelin and tesamorelin be used together?

Some protocols pair a GHRH analog like tesamorelin with a ghrelin-mimetic secretagogue like ipamorelin to target two different receptor pathways, and our tesamorelin/ipamorelin results article covers how that combination is evaluated. Any combination should be discussed with a knowledgeable clinician given tesamorelin’s specific FDA-approved indication.

Is tesamorelin stronger than CJC-1295/ipamorelin?

They’re not directly comparable in potency because they’re dosed differently and act through different mechanisms — tesamorelin is a single GHRH analog dosed in milligrams, while CJC-1295/ipamorelin combines two pathways dosed in micrograms. Neither is fully documented head-to-head in neutral clinical trial data.

Is CJC-1295/ipamorelin legal to buy?

Its legal and compounding status is unsettled: reporting suggests ipamorelin’s FDA compounding category has shifted, and CJC-1295 was reportedly not recommended for the 503A bulk substances list after a December 2024 committee review. Check current regulations with a licensed pharmacy before sourcing it.

Why is tesamorelin only approved for HIV-related fat loss?

Tesamorelin’s FDA approval, under the EGRIFTA brand, is specifically indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy based on trials supporting that indication. Off-label use for other goals happens but falls outside its approved labeling.

How do I track doses if I’m switching between mcg and mg peptides?

Because CJC-1295/ipamorelin is typically dosed in micrograms and tesamorelin in milligrams, unit mix-ups are a real risk when switching protocols. Using a dedicated tracking and reconstitution tool like Pep helps keep vial concentration, dose volume, and unit conversions accurate across compounds.